Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia

NEXT STORY
OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation
PREV STORY
Bone Therapeutics Provides Third Quarter 2020 Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Inventiva Reports First-half 2018 Financial Results and Provides a Corporate Update

 Inventiva Reports First-half 2018 Financial Results and Provides a Corporate Update Cash position at €75.9 ...

author_avatar
NASDAQ Market News

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

LONDON, May 11, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) ...

author_avatar
NASDAQ Market News

GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers

GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers GENFIT significantly contributes ...

author_avatar
NASDAQ Market News